ArticleNature genetics2018
Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis.
Open access · greenAbstract read
In one paragraph
Article in Nature genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Lymphocyte count polygenicity underlies dimethyl fumarate-associated lymphopenia in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Systematic review on genetic polymorphisms associated with idiosyncratic drug-induced liver injury (iDILI): iDILInet as an interactive visualization tool.Acta pharmaceutica Sinica. B · 2026Article
- IRF6 regulates adherens junction proteins and inflammatory cytokines in salivary acinar cells and its expression is elevated in Sjӧgren's syndrome.Archives of oral biology · 2025Article
- Genetic and Genomic Approaches to the Study of Drug-Induced Liver Injury.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- The multiple roles of interferon regulatory factor family in health and disease.Signal transduction and targeted therapy · 2024Review
- [Genetic susceptibility to drug-induced liver injury].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Multi-Tissue Transcriptome Study of Innate Immune Gene Expression Profiling Reveals Negative Energy Balance Altered the Defense and Promoted System Inflammation of Dairy Cows.Veterinary sciences · 2023Article
- Genetics of drug-induced liver injury: Current knowledge and future prospects.Clinical and translational science · 2023Review
- Sublytic C5b-9 Induces CCL3/4 Production and Macrophage Accumulation in Thy-1N Rats via PKC-α/p65/IRF-8 Axis.International journal of biological sciences · 2022Article
- Promoter Binding and Nuclear Retention Features of Zebrafish IRF Family Members in IFN Response.Frontiers in immunology · 2022Article
- Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.Frontiers in pharmacology · 2022Review
- Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations.Genes · 2020Article
- Safety perspectives on presently considered drugs for the treatment of COVID-19.British journal of pharmacology · 2020Review
- A Novel Combined Scientific and Artistic Approach for the Advanced Characterization of Interactomes: The Akirin/Subolesin Model.Vaccines · 2020Article
- Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease.Pharmacogenomics and personalized medicine · 2020Review
- Pharmacogenomics of COVID-19 therapies.NPJ genomic medicine · 2020Review
- Mutations in VP0 and 2C Proteins of Duck Hepatitis A Virus Type 3 Attenuate Viral Infection and Virulence.Vaccines · 2019Article
- Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.Pharmacology & therapeutics · 2019Review
- Drug-Induced Liver Injury: Highlights of the Recent Literature.Drug safety · 2019Review
- Replication study of GWAS risk loci in Greek multiple sclerosis patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 12 institutions in 4 countries.
Kaarina KowalecDivision of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Galen E B WrightDivision of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0003-2415-7339
Britt I DrögemöllerDivision of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0002-3348-5855
Folefac AminkengDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Amit P BhavsarBritish Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
Elaine KingwellDivision of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Eric M YoshidaDivision of Gastroenterology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Anthony TraboulseeDivision of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Ruth Ann MarrieDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Marcelo KremenchutzkyLondon Health Sciences Centre and Department of Clinical Neurological Sciences, Faculty of Medicine, Western University, London, Ontario, Canada.
Trudy L CampbellDalhousie Multiple Sclerosis Research Unit and School of Nursing, Dalhousie University, Halifax, Nova Scotia, Canada.
Pierre DuquetteDepartment of Neurosciences, Université de Montréal, Montreal, Quebec, Canada.
Naga ChalasaniDivision of Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA.
Mia WadeliusDepartment of Medical Sciences and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-6368-2622
Pär HallbergDepartment of Medical Sciences and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Zongqi XiaDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
Philip L De JagerCenter for Translational and Computational Neuroimmunology and Multiple Sclerosis Center, Department of Neurology, Columbia University Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-8057-2505
Joshua C DennyDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.
Mary F DavisDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT, USA.
Colin J D RossBritish Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada. colin.ross@ubc.ca.
Helen TremlettDivision of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. helen.tremlett@ubc.ca.ORCID http://orcid.org/0000-0001-5804-2535
Bruce C CarletonDivision of Translational Therapeutics, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada. bcarleton@popi.ubc.ca.
University of British Columbia · CAUppsala University · SEAgency for Science, Technology and Research · SGBrigham Young University · USBroad Institute · USDalhousie University · CAIndiana University School of MedicineUniversité de Montréal · CAUniversity of Manitoba · CAUniversity of Pittsburgh · USVanderbilt University Medical Center · USWestern University · CA
Funding
MICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH (MICHR) (UL1): (BPCA)UL1RR024986 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHANLEY, THOMAS P. · 2007 to 2011
$51.2MUNC CLINICAL AND TRANSLATIONAL SCIENCE AWARD: BPCAUL1RR025747 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUNGE, MARSCHALL S. · 2008 to 2011
$44.6MDrug Induced Liver Injury Network Data Coordinating CenterU01DK065176 · NIDDK · DUKE UNIVERSITY · PI Huiman X Barnhart · 2003 to 2026
$25.5MINDIANA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UL1): BPCAUL1RR025761 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$21.0MUnderstanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 2015 to 2019
$13.0MCoordinating Center for the Drug Induced Liver Injury Network (DILIN)U24DK065176 · NIDDK · DUKE UNIVERSITY · PI BARNHART, HUIMAN X · 2018 to 2022
$7.6MIU Clinical Center: Drug Induced Liver Injury NetworkU01DK065211 · NIDDK · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI NAGA P CHALASANI · 2003 to 2026
$7.5MUniversity of North Carolina Clinical Center for DILINU01DK065201 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PAUL B WATKINS · 2003 to 2026
$7.3MMichigan Hepatotoxicity Clinical Research Network Renewal 2018U01DK065184 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROBERT J FONTANA · 2003 to 2026
$7.0MThe Drug Induced Liver Injury Network (DILIN): Focus on Herbal and DietarySupplementsU01DK083027 · NIDDK · THOMAS JEFFERSON UNIVERSITY · PI Dina Halegoua-DeMarzio · 2008 to 2026
$7.0MUSC-UCLA Drug-Induced Liver Injury (DILI) Clinical Center.U01DK083020 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Lily Dara · 2008 to 2026
$5.9MLeveraging electronic health records to optimize treatment selection and response in multiple sclerosisR01NS098023 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Zongqi Xia · 2016 to 2026
$4.6MNCRR NIH HHS UL1 RR024986NCRR NIH HHS UL1 RR025747NCRR NIH HHS UL1 RR025761NIDDK NIH HHS U01 DK065176NIDDK NIH HHS U01 DK065184NIDDK NIH HHS U01 DK065193NIDDK NIH HHS U01 DK065201NIDDK NIH HHS U01 DK065211NIDDK NIH HHS U01 DK065238NIDDK NIH HHS U01 DK082992NIDDK NIH HHS U01 DK083020NIDDK NIH HHS U01 DK083023NIDDK NIH HHS U01 DK083027NIDDK NIH HHS U01 DK100928NIDDK NIH HHS U24 DK065176NIGMS NIH HHS P50 GM115305NINDS NIH HHS K08 NS079493NINDS NIH HHS R01 NS098023Wellcome Trust
Abstract
Multiple sclerosis (MS) is a disease of the central nervous system treated with disease-modifying therapies, including the biologic, interferon-β (IFN-β). Up to 60% of IFN-β-exposed MS patients develop abnormal biochemical liver test results
Indexed as
Chemical and Drug Induced Liver InjuryFemaleGenetic VariationGenome-Wide Association StudyHumansInterferon-betaInterferon Regulatory FactorsMaleMultiple SclerosisInterferon-betaInterferon Regulatory FactorsIRF6 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.